

WILLIAMS, MORGAN & AMERSON, P.C. TECH CEN

10333 RICHMOND, STE. 1100, HOUSTON, TEXAS 77042

(713) 934-7000 FAX: (713) 934-7011

Danny L. Williams
Terry D. Morgan
J. Mike Amerson
Kenneth D. Goodman
Jeffrey A. Pyle
Jaison C. John
Ruben S. Bains
Scott F. Diring

Shelley P.M. Pyssey, Ph.D.* Mark D. Moore, Ph.D.* Raymund F. Eich, Ph.D.*

Daren C. Davis* Stephanie A. Wardwell, Ph.D.* Mark W. Sincell, Ph.D.*

*Patent Agent

WRITER'S DIRECT DIAL: (713) 934-4079

September 18, 2003

File: 4001.002282

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

September 18, 2003

Date

Shelley P.M. Fussey

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RE:

U.S. Application Serial No. 09/351,862; Entitled "Cancer Treatment Kits Using Antibodies to Aminophospholipids"; by Thorpe and Ran; Client Reference: UTSD:549--1

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, PTO Form 1449 and copies of References C71-C79.

No fees are believed to be due in connection with the filing of these materials, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002282.

WILLIAMS, MORGAN & AMERSON, P.C.

Commissioner for Patents September 18, 2003 Page 2

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Williams, Morgan & Amerson, P.C. Customer No. 23720

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458 Patent Agent

Encls.



CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

September 18, 2003

Date

Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

ANTIBODIES TO

AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Final Official Action has been received in the present application. However, this

Supplemental Information Disclosure Statement is being submitted in an abundance of caution

and should be enterable under 37 C.F.R. § 1.97(d) in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed

in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent

office in a counterpart foreign application of the present case. The listed documents were

brought to the attention of Applicants' undersigned representative on or about July 08, 2003,

which date is less than three months ago. Applicants' undersigned representative was advised of

the listed documents by patent counsel to the licensee of the present application, which was said

to have arisen as a result of counseling the licensee regarding business matters. The listed

documents are being made of record within three months of the pertinent teleconference held on

or about July 08, 2003.

Should any fees under 37 C.F.R. §§ 1.97(d) and 1.17(p) be due, the Examiner should

contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson

Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.

Customer No. 23720

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

10333 Richmond, Suite 1100 Houston, Texas, 77042

(713) 934-4079

Date: September 18, 2003

2

Page 1 of 2 Serial No. Atty. Docket No. Form PTO-1449 (modified) 4001.002282 09/351,862 st of Patents and Publications for Applicant's Applicant Thorpe and Ran INFORMATION DISCLOSURE STATEMENT Filing Date: Group: (Use several sheets if necessary) July 12, 1999 1617 **Foreign Patent Documents U.S. Patent Documents** Other Art See Page See Page See Page 1 and 2

-			U.S. Patent I	Documents			
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
			Foreign Paten	t Documents	<u> </u>		
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation		
	C71	Becker and Brocker, "Antiphospholipid Syndrome Associated with Immunotherapy for Patients with Melanoma," <i>Cancer</i> , 75:2785, 1995		
	C72	Bevers et al., "Changes in Membrane Phospholipid Distribution During Platelet Activation," Biochim. Biophys. Acta., 122:429-436, 1982.		
	C73	Connor et al., "Exposure of Phosphatidylserine in the Outer Leaflet of Human Red Blood Cells," J. Biol. Chem., 736:57-66, 1983.		
·	C74	Fadok et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages," J. Immunol., 148:2207-2216, 1992.		
	C75	Katsuragawa et al., "Monoclonal Antiphosphatidylserine Antibody Reactivity Against Human First-Trimester Placental Trophoblasts," Am. J. Obstetr. Gynecol., 172:1592-1597, 1995.		
	C76	Maneta-Peyret et al., "Demonstration that Anti-Phospholipid Auto-Antibodies React with Both Anionic and Zwitterionic Phospholipids," <i>Immunol. Lett.</i> , 35:141-146, 1993.		
	C77	Naldi et al., "Antiphospholipid Antibodies and Melanoma: A Link?," Dermatology, 184:156, 1992.		

Examiner:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT

Atty. Docket No. 4001.002282

Serial No. 09/351,86

Applicant

Thorpe and Ran

Filing Date: Group: July 12, 1999 1617

U.S. Patent Documents See Page

(Use several sheets if necessary)

Foreign Patent Documents See Page

Other Art See Page 1 and 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation		
	C78	Rote et al., "Expression of Phosphatidylserine-Dependent Antigens on the Surface of Differentiating BeWo Human Choriocarcinoma Cells," Am. J. Rep. Immunol., 33:114-121, 1995.		
	C79	Zwaal and Schroit, "Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells," <i>Blood</i> , 89:1121-1132, 1997.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.